Citius Oncology, INC. (CTOR) — 8-K Filings

All 8-K filings from Citius Oncology, INC.. Browse 27 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (27)

Citius Oncology Files 8-K: Material Agreement, Equity Sales — Dec 10, 2025 Risk: medium
On December 8, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
Citius Oncology Files 8-K Report — Dec 1, 2025 Risk: low
On December 1, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial St
Citius Oncology Files 8-K: Director Changes, Officer Comp, Shareholder Votes — Oct 27, 2025 Risk: medium
On October 27, 2025, Citius Oncology, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of
Citius Oncology Files 8-K Report — Oct 23, 2025 Risk: low
On October 23, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Th
Citius Oncology Files 8-K: Equity Sale, Officer Changes, Financials — Sep 19, 2025 Risk: medium
On September 19, 2025, Citius Oncology, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The filing also announced the departure o
Citius Oncology Files 8-K with Key Agreements and Disclosures — Sep 10, 2025 Risk: medium
On September 9, 2025, Citius Oncology, Inc. filed an 8-K report detailing several key events. The company entered into a Material Definitive Agreement, reported
Citius Oncology Files 8-K Report — Aug 18, 2025 Risk: medium
On August 18, 2025, Citius Oncology, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporate
Citius Oncology Files 8-K: Material Agreement and Other Events — Jul 18, 2025 Risk: medium
On July 16, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements a
Citius Oncology Files 8-K: Other Events — Jun 27, 2025 Risk: low
On June 26, 2025, Citius Oncology, Inc. filed an 8-K report detailing an 'Other Events' filing. The company, formerly known as TenX Keane Acquisition until Marc
Citius Oncology Files 8-K Report — Jun 17, 2025 Risk: low
On June 17, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company,
Citius Oncology Faces Delisting Concerns — Apr 25, 2025 Risk: high
On April 23, 2025, Citius Oncology, Inc. filed an 8-K to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly know
Citius Oncology Enters Material Definitive Agreement — Apr 3, 2025 Risk: medium
On March 28, 2025, Citius Oncology, Inc. entered into a material definitive agreement. The company, formerly known as TenX Keane Acquisition until March 15, 202
Citius Oncology Files 8-K Report — Feb 6, 2025 Risk: low
On February 6, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The compan
Citius Oncology Files 8-K Report — Jan 7, 2025 Risk: low
On January 7, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company
Citius Oncology Files 8-K Report — Jan 6, 2025 Risk: low
On January 6, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
Citius Oncology Files 8-K Report — Nov 12, 2024 Risk: low
On November 11, 2024, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specif
Citius Oncology Enters Material Definitive Agreement — Sep 13, 2024 Risk: medium
On September 9, 2024, Citius Oncology, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, the ot
Citius Oncology Files 8-K Report — Sep 5, 2024 Risk: low
On September 5, 2024, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
CITIUS ONCOLOGY (CTSO) Files 8-K: Acquisition, Equity Sales, Accountant Change — Aug 16, 2024 Risk: medium
On August 12, 2024, Citius Oncology, Inc. (formerly TenX Keane Acquisition) filed an 8-K detailing several significant events. These include entering into a mat
TenX Keane Acquisition Combines with 03 Life Sciences — Aug 5, 2024 Risk: medium
On August 2, 2024, TenX Keane Acquisition announced a significant business combination with 03 Life Sciences, a pharmaceutical preparations company. The filing
TenX Keane Acquisition Signs Material Definitive Agreement — Jul 19, 2024 Risk: medium
On July 17, 2024, TenX Keane Acquisition entered into a material definitive agreement related to its business combination. The company, incorporated in the Caym
TenX Keane Acquisition Enters Material Agreement — Jun 18, 2024 Risk: medium
On June 17, 2024, TenX Keane Acquisition entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
TenX Keane Acquisition Files 8-K — Jun 6, 2024 Risk: low
On May 31, 2024, TenX Keane Acquisition filed an 8-K report detailing other events. The company, incorporated in the Cayman Islands, is involved in the pharmace
TenX Keane Acquisition Enters Material Definitive Agreement — May 21, 2024 Risk: medium
On May 17, 2024, TenX Keane Acquisition entered into a material definitive agreement, likely related to its business as a pharmaceutical preparations company. T
TenX Keane Acquisition Signs Material Definitive Agreement — Apr 29, 2024 Risk: medium
On April 26, 2024, TenX Keane Acquisition entered into a material definitive agreement related to its business. The company, incorporated in the Cayman Islands,
TenX Keane Acquisition Reports Capital Structure Changes — Jan 18, 2024
TenX Keane Acquisition filed an 8-K on January 18, 2024, reporting an event on January 17, 2024, related to its corporate structure. The filing indicates change
TenX Keane Acquisition Updates Business Address in 8-K Filing — Jan 10, 2024
TenX Keane Acquisition, a SPAC, filed an 8-K on January 10, 2024, to update its business address to 420 Lexington Ave, Suite 2446, New York, NY 10170. This admi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX